Virtual Care to Improve Heart Failure Outcomes (VITAL-HF)

Prior treatment

• Optimized or nearly-optimized on evidence-based medical therapies for HFrEF as determined by local investigator.
• Chronic use of intravenous inotropic medications including milrinone, dobutamine, or dopamine
• Prior heart transplant
• Currently receiving hospice care
• Chronically resides in an assisted living or skilled nursing facility where food and medications are managed by facility personnel

Other illness

• Terminal illness other than HF with a life expectancy of less than 1 year as determined by the enrolling clinician-investigator

Lab values

• eGFR of \<20 mL/min/1.73m2 or ongoing chronic dialysis at screening

Other

• Current pregnancy
• Current or planned left ventricular assist device

• Age \>18 years of age
• Diagnosis of HF and LVEF \<40% on most recent imaging assessment within 1 year prior to screening. Any validated method for assessing LVEF may be used for enrollment including echocardiogram, cardiac magnetic resonance imaging, etc. For participants with an LVEF reported qualitatively (e.g., moderate LV dysfunction) or as a range on the most recent imaging assessment that includes 40% (e.g., 35-45%), then the site investigator should review the imaging study and determine if the participant has an LVEF \<40%. Participants with a new diagnosis of HFrEF may be enrolled. The enrollment will be monitored to ensure no more than 50% of the total cohort have new-onset HFrEF.
• Access to a smartphone including through a family member of caregiver
• Fluent in written and spoken English